Loading...
India's famotidine imports from CHINA total $66 across 1 shipments from 1 foreign suppliers. M/S WUXI YUEYUAN TECHNOLOGY CO leads with $66 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include AUROBINDO PHARMA LTD. This corridor reflects India's pharmaceutical import demand for famotidine — a concentrated sourcing relationship with select suppliers from CHINA.
M/S WUXI YUEYUAN TECHNOLOGY CO is the leading Famotidine supplier from CHINA to India, with import value of $66 across 1 shipments. The top 5 suppliers — M/S WUXI YUEYUAN TECHNOLOGY CO — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | M/S WUXI YUEYUAN TECHNOLOGY CO | $66 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD | $66 | 1 | 100.0% |
CHINA → India trade corridor intelligence
As of April 2026, the China to India trade corridor for pharmaceutical imports, including Famotidine formulations, is operating with moderate efficiency. Port congestion at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra has been reported, leading to delays in clearance times. Freight rates have experienced fluctuations due to global supply chain dynamics, impacting the cost-effectiveness of imports. The exchange rate between the Indian Rupee (INR) and the Chinese Yuan (CNY) has remained relatively stable, providing predictability in transaction costs. Importers are advised to monitor these factors closely to optimize their supply chain operations.
The Indian government's Production Linked Incentive (PLI) scheme, introduced in 2024, aims to boost domestic manufacturing and reduce reliance on imports, including pharmaceutical formulations. This policy may influence the volume of finished Famotidine formulations imported from China, as domestic production becomes more competitive. Import substitution policies are being evaluated to assess their impact on reducing import dependency. While the PLI scheme encourages self-reliance, it also acknowledges the need for imported formulations to meet specific market demands not yet addressed by domestic manufacturers.
India and China have engaged in bilateral trade agreements to facilitate the import and export of pharmaceutical products, including finished formulations. Negotiations have focused on mutual recognition of Good Manufacturing Practices (GMP) to streamline the approval process for imports. These agreements aim to enhance trade relations, ensure product quality, and address regulatory challenges, benefiting both countries' pharmaceutical industries.
The landed cost of importing finished Famotidine formulations from China to India includes several components:
Per-unit estimates vary based on the product's value, shipping terms, and prevailing rates. Importers should calculate the total landed cost by summing these components to determine the final cost per unit.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Famotidine into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) oversees the registration of both the foreign manufacturer and the product. An Import Registration Certificate is mandatory for each product intended for import. The application process involves submitting Form 40 or 41, along with necessary documents such as a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining registration varies but typically ranges from several months to a year, depending on the completeness of the application and regulatory review. For formulations under HS Code 30049039, specific requirements include detailed product information, manufacturing site details, and compliance with Indian Pharmacopoeia standards.
Upon arrival in India, imported pharmaceutical formulations containing Famotidine are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, is required to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors ensure that the products meet all regulatory standards before clearance. Batch-wise testing is mandatory, and any batch failing to meet the required standards is subject to rejection or destruction, as per CDSCO guidelines.
Between 2024 and 2026, CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements with China have been established to streamline the import process, including mutual recognition of Good Manufacturing Practices (GMP), which may facilitate smoother trade in pharmaceutical products. These developments aim to balance the promotion of domestic industry with the need for imported formulations.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Famotidine formulations to meet the demand for branded or patented products not manufactured domestically, as well as specific dosage forms required by the market. The domestic capacity may not fully satisfy the demand for all Famotidine formulations, leading to reliance on imports. The market size for Famotidine formulations in India is substantial, with a total export market of $55.8 million across 152 exporters to 66 countries, indicating a significant domestic consumption. This underscores the importance of imports in fulfilling the therapeutic needs of the Indian population.
The import of finished pharmaceutical formulations containing Famotidine under HS Code 30049039 is subject to a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% is levied on the BCD. Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which are subject to change. There are no specific exemptions or preferential duty rates for imports from China under this HS code. The total landed duty percentage combines these components, impacting the final cost of imported formulations.
India sources finished Famotidine formulations from China due to competitive pricing, established manufacturing capabilities, and the availability of specific formulations not produced domestically. China's pharmaceutical industry offers a range of products that meet international quality standards, making it a viable source for India's import needs. While other countries like Germany and the United States also supply Famotidine formulations, China's competitive pricing and manufacturing scale provide a distinct advantage. China's share in India's Famotidine import market is significant, reflecting its competitive position.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Famotidine formulations from China due to several strategic reasons:
These factors contribute to India's reliance on Chinese imports to meet the therapeutic needs of its population.
When comparing China to other origins like the European Union (EU) and the United States (US) as sources for finished Famotidine formulations, several factors come into play:
China's unique advantage lies in its ability to offer a combination of competitive pricing and quality, making it a preferred source for India's Famotidine imports.
Indian importers face several supply chain risks when sourcing finished Famotidine formulations from China:
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Famotidine suppliers from CHINA to India include M/S WUXI YUEYUAN TECHNOLOGY CO. The leading supplier is M/S WUXI YUEYUAN TECHNOLOGY CO with import value of $66 USD across 1 shipments. India imported Famotidine worth $66 USD from CHINA in total across 1 shipments.
India imported Famotidine worth $66 USD from CHINA across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Famotidine sourced from CHINA include AUROBINDO PHARMA LTD. The largest buyer is AUROBINDO PHARMA LTD with $66 in imports across 1 shipments.
The total value of Famotidine imports from CHINA to India is $66 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists